Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany

Aims Treatment of iron deficiency (ID) in patients with heart failure (HF) with intravenous iron substitution [ ferric carboxymaltose (FCM)] has previously shown significant improvements in exercise capacity, New York Heart Association (NYHA) functional class, quality of life, and reduction of hospitalization. The aim of this study was to estimate the budget impact of FCM treatment for patients with HF and ID. Methods and results Individual patient data from four double-blind randomized controlled trials were pooled for this analysis. Expected outcomes were modelled for a treatment period of 1 year, using multivariate statistical methods. Associated unit costs were derived from claims data. Budget impact was calculated from the perspective of the Statutory Health Insurance. Multiple deterministic sensitivity analyses were performed. The annual budget impact for therapy with FCM vs. no-iron therapy was (sic)2 735 505 and (sic)2 695 474 for 1000 patients, respectively, resulting in additional annual costs of (sic)40.03 for each treated patient. Main costs drivers are the FCM treatment cost and cost of hospitalizations due to HF worsening. FCM therapy compared with no-iron therapy resulted in reduced cost per 1000 patients: for reduced hospitalization due to HF worsening ( 52 vs. 129 hospitalizations amounting to (sic)230 591 vs. (sic)597 078), for reduced other medication ((sic)1 611 007 vs. (sic)1 679 908), fewer outpatient visits ((sic)332 523 vs. (sic)378 019), and home visits ((sic)29 627 vs. (sic)40 469). Sensitivity analyses showed robustness of the results. Conclusions Therapy with FCM has a minimal budget impact of (sic)40 031 per 1000 patients per year. This budget impact translates into reduced and shorter hospitalizations and improved symptomatic status of the patients.